Last Updated : July 16, 2019
Details
FilesGeneric Name:
buprenorphine
Project Status:
Complete
Therapeutic Area:
Opioid use disorder, treatment
Manufacturer:
Indivior Canada Ltd.
Call for patient/clinician input open:
Brand Name:
Sublocade
Project Line:
Reimbursement Review
Project Number:
SR0579-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate-to-severe opioid use disorder in adults. Sublocade should be used as part of a complete treatment plan that includes counseling and psychosocial support.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Opioid use disorder, treatment
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2 |
|
|---|---|
| Call for patient input posted | July 25, 2018 |
| Patient group input closed | September 14, 2018 |
| Clarification:
- No patient input submission received |
|
| Submission received | December 20, 2018 |
| Submission accepted for review | January 11, 2019 |
| Review initiated | January 14, 2019 |
| Draft CADTH review report(s) sent to applicant | March 28, 2019 |
| Comments from applicant on draft CADTH review report(s) received | April 08, 2019 |
| Redaction requests from applicant on draft CADTH review report(s) received | April 15, 2019 |
| CADTH review team's comments on draft CADTH review report(s) sent to applicant | May 03, 2019 |
| Canadian Drug Expert Committee (CDEC) meeting | May 15, 2019 |
| CDEC recommendation & redacted CADTH review report(s) sent to applicant and drug plans | May 29, 2019 |
| Embargo period ended and validation of redacted CADTH review report(s) received | June 12, 2019 |
| CDEC Final Recommendation issued to applicant and drug plans | June 19, 2019 |
| CDEC Final Recommendation posted | June 21, 2019 |
| Final CADTH review report(s) posted | July 16, 2019 |
Files
Last Updated : July 16, 2019